Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
- Address
- 185 Rue Raymond Losserand, 75014 Paris, France
Nervous System Diseases
The Institut de Neuromodulation is conducting studies that explore innovative therapies for acute ischemic stroke, aiming to improve functional recovery and quality of life.
- Acute ischemic stroke
- Aneurysmal subarachnoid hemorrhage
- Traumatic brain injury
- Intracerebral hemorrhage
- Diffuse intrinsic pontine glioma
These efforts at Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience reflect a commitment to advancing neurocritical care.
Mental Disorders
Clinical research focuses on novel interventions for major depressive disorder and treatment‑resistant forms, seeking faster symptom relief.
- Major Depressive Disorder
- Treatment‑Resistant Depression
- Generalized Anxiety Disorder
- Ultra High Risk of Psychosis
- Treatment‑Resistant Schizophrenia
The site’s multidisciplinary team integrates psychiatry and neuromodulation to enhance mental health outcomes.
Cardiovascular Diseases
Trials evaluate strategies to prevent secondary events after ischemic stroke and to optimize anticoagulation in patients with vascular pathology.
- Ischemic stroke
- Large vessel occlusion stroke
- Aneurysmal subarachnoid hemorrhage
- Anticoagulation after intracerebral hemorrhage
- Endovascular coiling of unruptured aneurysms
Research at Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience aims to reduce mortality and disability from vascular disorders.
Immune System Diseases
Investigators are testing immunomodulatory approaches for myasthenia gravis and sickle cell disease, targeting disease progression and organ protection.
- Myasthenia gravis
- Sickle cell disease
- Hospital‑acquired pneumonia
- Sepsis in ICU
- Immune‑mediated neuroinflammation in Alzheimer disease
The institute leverages its expertise in neuromodulation to modulate immune pathways for better patient outcomes.
Neoplasms
Oncologic studies address aggressive brain tumors such as diffuse intrinsic pontine glioma, testing targeted agents combined with radiotherapy.
- Diffuse intrinsic pontine glioma
- Other diffuse midline gliomas
- Brain arteriovenous malformations
- Glioma
- High‑grade pediatric brain tumors
Through collaborations, the site strives to bring precision medicine to patients with rare central nervous system cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 24 therapeutic areas and 15 of 285 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 259 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 62 by active trials.
lock +61 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +26 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
lock Showing 1 of 172 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer | T.O.A.D. Oncology S.A. | Phase I/II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 285 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 20 | Unknown | 2019-03-21 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.